Reduced-dose IMRT with cisplatin meets predetermined benchmarks for PFS and swallowing-related QOL

Results of the NRG Oncology clinical trial NRG-HN002 indicated that the combination of intensity-modulated radiotherapy (IMRT) and cisplatin was able to meet acceptability criteria for progression-free survival (PFS) and swallowing-related quality of life for patients who have p16-positive, non-smoking-associated oropharyngeal cancer. These results were highlighted during the plenary session at the American Society for Radiation Oncology's (ASTRO) Annual Meeting in September 2019 and this presentation was the recipient of ASTRO and ABR Foundation's Steven A. Leibel Memorial Award at the Meeting.

NRG-HN002 was designed with two parallel experimental arms, consisting of either IMRT with cisplatin over six weeks or modestly accelerated IMRT alone over five weeks. The primary goal of the trial was to determine which would achieve an acceptable PFS rate without unacceptable swallowing-related quality of life as measured by the MD Anderson Dysphagia Inventory (MDADI). Additionally, overall survival (OS) was tracked as a secondary endpoint among patients on the treatment arms. Following treatment, the 2-year PFS rate was 90.5% and the 1-year mean of MDADI score was 85.3 points for patients that received IMRT and cisplatin. These rates indicate that IMRT and cisplatin treatment met the acceptability criteria for both 2-year PFS and 1-year MDADI. Patients on the IMRT and cisplatin arm reported higher rates of grade 3 or greater acute toxicities than patients who received IMRT alone, but grade 3 or greater late toxicity rates and overall survival rates were statistically similar on each treatment arm.

"Based on the and the 2-year PFS estimate of 90.5% for the IMRT and cisplatin arm, there is data evidence to conclude that the 2-year PFS for the IMRT and cisplatin arm in this population is greater than 85%. In the radiation alone arm, there is not enough data evidence to conclude that the 2-year PFS in this population is greater than 85%, despite the 2-year PFS estimate of 87.6% in this arm. Both treatment arms were able to pass the MDADI threshold," stated Sue S. Yom, MD, Ph.D., of the University of California, San Francisco and principal investigator of NRG-HN002.

NRG-HN002 had 306 patients that were eligible and randomly assigned to receive either IMRT with cisplatin (157) or IMRT alone (149). Of 157 patients assigned to received IMRT and cisplatin, 80.9% completed 5 or more cisplatin cycles and 72.6% received at least 200mg/m2. On the IMRT and cisplatin arm there were 15.1% grade 4 and 64.5% grade 3 acute toxicities, 1.3% grade 4 and 20.0% grade 3 late toxicities reported. Patients on the IMRT alone treatment arm experienced 2.0% grade 4 and 50.3% grade 3 acute toxicities and 1.4% grade 4 and 16.7% grade 3 late toxicities. No grade 5 toxicities were reported on either arm. Estimated 2-year OS rates were 96.7% for IMRT and treatment and 97.3% for IMRT alone. Nine patients withdrew consent from the trial and five participants did not have 2-year assessments to include in the results.

Explore further

Proton therapy for prostate cancer is advantageous to imrt according to new study

More information: Yom SS et al. (2019, September). NRG-HN002: A Randomized Phase II Trial for Patients with p16-Positive, Non-Smoking-Associated, Locoregionally Advanced Oropharyngeal Cancer. Paper presented at the annual meeting of the American Society for Radiation Oncology, Chicago, IL.
Provided by NRG Oncology
Citation: Reduced-dose IMRT with cisplatin meets predetermined benchmarks for PFS and swallowing-related QOL (2019, September 17) retrieved 17 October 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more